YIH
HRMY icon

Y-Intercept (HK)’s Harmony Biosciences HRMY Stock Holding History

Y-Intercept (HK)’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.81M Sell
49,649
-97,395
-66% -$3.07M 0.04% 756
2026
Q1 		$4.12M Buy
147,044
+107,449
+271% +$3.52M 0.08% 407
2025
Q4 		$1.48M Sell
39,595
-18,895
-32% -$621K 0.03% 775
2025
Q3 		$1.61M Buy
58,490
+9,036
+18% +$311K 0.04% 731
2025
Q2 		$1.56M Buy
+49,454
New +$1.59M 0.04% 720
2025
Q1 		– Sell
-27,061
Closed -$931K – 1375
2024
Q4 		$931K Buy
27,061
+20,070
+287% +$690K 0.06% 457
2024
Q3 		$280K Buy
+6,991
New +$246K 0.02% 1047

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Y-Intercept (HK)'s HRMY Position: Q2 2026 in Review

Y-Intercept (HK) reduced its Harmony Biosciences (HRMY) stake by 66% in Q2 2026, selling an estimated $3.07M and leaving 49,649 shares worth $1.81M. The position accounts for 0.04% of the portfolio, ranked #756.

Y-Intercept (HK) first reported a position in HRMY in Q3 2024 and has held it in 7 quarters since. The position peaked at $4.12M in Q1 2026. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Y-Intercept (HK) held 49,649 shares of Harmony Biosciences worth $1.81M as of Q2 2026.
  • Y-Intercept (HK) sold 97,395 Harmony Biosciences shares in Q2 2026, an estimated $3.07M.
  • Harmony Biosciences made up 0.04% of Y-Intercept (HK)'s portfolio in Q2 2026, its #756 holding.
  • Y-Intercept (HK) first reported a position in Harmony Biosciences in Q3 2024 and has held it in 7 quarters since.
  • Y-Intercept (HK)'s Harmony Biosciences position peaked at $4.12M in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.